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Background.WeanalyzedradicalTUR-PCaagainstlocalizedprostatecancer.PatientsandMethods.Seventy-nineoutof209patients
with prostate cancer in one lobe were studied. Patients’ age ranged from 58 to 91 years and preoperative PSA, 0.70 to 17.30ng/mL.
In other 16 additional patients we performed focal TUR-PCa. Patients’ age ranged from 51 to 87 years and preoperative PSA,
1.51 to 25.74ng/mL. Results. PSA failure in radical TUR-PCa was 5.1% during the mean follow-up period of 58.9 months. The
actuarial biochemical non-recurrence rate was 98.2% for pT2a and 90.5% for pT2b. Bladder neck contracture occurred in 28
patients (35.4%). In 209 patients, pathological study revealed prostate cancer of the peripheral zone near the neurovascular bundle
bilaterally in 25%, unilaterally in 39% and no cancer bilaterally in 35%, suggesting the possibility of focal TUR-PCa. Postoperative
PSA of 16 patients treated by focal TUR-PCa was stable between 0.007 and 0.406ng/mL at 24.2 months’ follow-up. No patients
suﬀered from urinary incontinence. Bladder neck contracture developed in only 1 patient and all 5 patients underwent nerve-
preserving TUR-PCa did not show erectile dysfunction. Conclusion. Focal TUR-PCa was considered to be a promising option
among focal therapies against localized prostate cancer.
1.Introduction
Current standard radical surgery [1–3] against localized
prostate cancer (PCa) has possible risks to disturb urinary
continence or erectile function because they target the whole
prostate. Many operative procedures [4–6] were introduced
to improve the recovery of postoperative sexual function
and urinary incontinence, such as bladder neck suspension
or reconstruction, reconstruction of the rhabdosphincter,
periurethral suspension of the dorsal vein complex/urethral
complex and preservation of the neurovascular bundle to
preserveerectilefunction[7].Butallthesehavefailedtosolve
the problems completely until now. Irradiation therapy such
as brachytherapy [8], three-dimensional conformal radia-
tion therapy 3D-CRT [9], or intensity-modulated radiation
therapy (IMRT) [10] cannot completely prevent urinary
incontinence, intestinal damage, or erectile dysfunction as
well.
As the number of patients with low-volume, low-grade
localized prostate cancer increased after the introduction
of PSA into health check-up program, less invasive focal
therapy has been proposed because of possible advantages
of both cancer control and quality of life. Cryotherapy [11,
12] and high-intensity focused ultrasound (HIFU) [13, 14]
are current main procedures of focal therapy but are still
considered experimental.
We previously reported that radical transurethral resec-
tion of prostate cancer (RTUR-PCa) could be a radical
therapy against localized prostate cancer [15]. We then
referred to the possibility of focal transurethral resection
of prostate cancer (FTUR-PCa), the procedure in which we
mainly resected the aﬀected lobe of the prostate [16]. We2 Advances in Urology
made a retrospective analysis of RTUR-PCa against localized
prostate cancer to evaluate whether FTUR-PCa could be a
valid focal therapy. We here report our result of FTUR-PCa,
too.
2. Patientsand Methods
2.1. Cases of RTUR-PCa as a Database to Estimate FTUR-
PCa. Between December 2003 and July 2009, a total of 261
RTUR-PCa were performed under spinal anesthesia in 209
patients with localized prostate cancer. Clinical stages were
determined according to the UICC TNM staging system of
1997. We performed bone scintigraphy and computerized
tomographyforthepurposeofmetastaticworkupinpatients
who had initial PSA levels of 20ng/mL or more. And we
recommended the patients who had PSA level between 10
and 20ng/mL and higher Gleason score to undertake such
examinations with some of them having refused to take. We
informed the patients that the procedure was not a standard
radical surgery, and those who refused this procedure were
excluded from the study. We also excluded patients who
might not tolerate standard transurethral resection of the
prostate (TURP). Patients who gave the written informed
consent were eligible for the study in the order they were
given a diagnosis of localized prostate cancer. Institutional
review board approved the TUR-PCa program after a
preliminary study.
2.2. Retrospective Analysis to Evaluate the Eﬃcacy and Safety
of FTUR-PCa. We thought that the most appropriate indi-
cation of focal therapy should be localized prostate cancer in
one lobe. We reviewed RTUR-PCa cases to ﬁnd patients to
match such criteria. Seventy-nine of the above 209 RTUR-
PCa patients diagnosed to have prostate cancer in one side
of the lobes were included in the present study. In 74 out
of these 79 patients, cancer was detected by ultrasound-
guided transrectal needle biopsy, and in the other 5 patients
prostate cancer was incidentally detected after TURP for
benign prostate hyperplasia (BPH). We obtained a total of 14
biopsy samples per case from the peripheral and transition
zone including far lateral part, dividing the prostate into base
(2 cores), upper middle part (2 cores), lower middle part
(6 cores), and apex (4 cores), and we marked at the dorsal
end to obtain tumor maps. In the patients underwent TURP;
after resecting most of the transition and central zone, we
made a slightly deeper resection dividing the residual thin
transitionzoneandperipheralzoneinto6partsandcollected
theresectedspecimensseparatelytoidentifytheaﬀectedsites
by pathological examination (advanced TURP) [15].
We performed 93 RTUR-PCa in 79 patients under spinal
anesthesia. Patients ranged from 58 to 91 years old (mean ±
SD, 73.9 ± 6.6; median, 74.0) and preoperative PSA, 0.70
to 17.30ng/mL (mean ± SD, 5.77 ± 3.51; median, 4.57).
Chlormadinone acetate was administered for a mean period
of 4.6 months in 52 patients.
2.3.FocalTUR-PCa. BetweenJuly2007andSeptember2011,
weperformedFTUR-PCain16patients.FTUR-PCaincludes
twodiﬀerentprocedures:inoneprocedureweradicallyresect
the aﬀected one lobe with unaﬀected lobe being resected as
advanced TURP for BPH (one lobe radical TUR), and in the
other procedure we radically resect both lobes except for the
prostatetissuesneartheneurovascularbundle(nervesparing
radical TUR) based on the tumor mapping. Patients ranged
from 51 to 87 years old (mean ± SD, 68.9 ± 9.6; median,
70.0) and preoperative PSA, 1.51 to 25.74ng/mL (mean ±
SD, 7.87 ± 6.35; median, 6.19). Chlormadinone acetate was
not administered in this group.
2.4. Surgical Procedure and Followup. One urologic surgeon
(M. Morita) performed all operations. We used a standard
TURP setup with an irrigation pressure of 80cm H2Oa n d
an irrigation rate of 250mL/min using D-sorbitol solution.
After resecting almost all the transition and central zone, we
tried to resect and fulgurate the peripheral zone completely
especiallywherecancerwasdetectedbybiopsy.Theresection
was performed as deep as adipose tissue was identiﬁed and
as distal as the external sphincter was identiﬁed. But we did
not resect prostate tissues until adipose tissue was exposed
all around the operative ﬁeld. We aggressively fulgurated the
area adjacent to where adipose tissue was exposed because
theremainingprostatetissuecouldbeconsideredathinlayer.
We especially paid attention not to distend the bladder too
muchtopreventahighirrigationpressureandresultantTUR
syndrome. Special attention was also paid to avoid injury
to Santorini’s plexus and the rectum. The procedure was
started from the 12 o’clock position, dividing the prostate
into6parts,andresectedspecimenswereseparatelycollected
from each part to examine the distribution of cancer. The
seminal vesicle was partially resected at its attached part
to the prostate between the 4 and 8 o’clock positions to
determine the invasion of cancer. Finally the verumontanum
was resected to achieve the complete resection of prostate
tissue.Abagcatheterwasremovedonthethirdpostoperative
day.
Postoperative PSA was measured every two months
starting two months after the operation. PSA failure was
suspected when PSA levels showed a consecutive rise over
0.2ng/mL.ButwhenthePSAlevelreachedaplateaubetween
0.2 and 1.0ng/mL, we did not immediately think that the
patients were in a treatment failure. This was also applied to
the indication of the second RTUR-PCa. We evaluated stress
urinary incontinence by asking patients the postoperative
status of urinary leak on a cough or a sneeze and needs for
urinary pads.
3. Results
3.1. Retrospective Analysis Based on the Results of Radical
TUR-PCa. The mean follow-up period of 79 patients was
58.9 ± 17.0 months (mean ± SD; median, 60.5; range, 15–
88). The operation time ranged between 65 and 120 minutes
(mean ± SD, 79.9 ± 15.2; median, 80.0), and the resected
tissue weight was between 5.0 and 37.0 grams (mean ± SD,
13.3 ± 6.4; median, 12.0). The preoperative PSA value wasAdvances in Urology 3
5.77 ± 3.51ng/mL (mean ± SD; median, 4.57; range, 0.70–
17.3). Clinical stages were as follows: T1b, 28 cases; T1c, 47;
T2, 4; and pathological stages: pT2a, 56 cases; pT2b, 21; pT3,
2( Table 1). Gleason scores were: 4, 3 cases; 5, 3; 6, 27; 7, 28;
8, 12; 9, 6 (Table 2).
One patient died of cerebrovascular accident 15 months
postoperatively with a low PSA value of 0.012ng/mL. No
patients died of prostate cancer. Sixty-four patients had
stablePSAaftertheﬁrstoperation.Thesecondoperationwas
required in 14 patients after a mean period of 16.4 months
(mean ± SD, 16.4 ± 7.5; median, 16.0; range, 6.4 to 30.5)
due to rising PSA levels. Resected tissue weight was between
5.0 and 12.0 grams (mean ± SD, 6.9 ± 1.6; median, 12.0).
No cancer was detected by pathological examination in 3
patients. The second operation was required in 10 (40.0%)
out of 25 patients before April 2006 but in only 4 (7.0%) out
of 54 patients after that time, suggesting that there seemed to
be a learning curve for the operative technique.
Attheﬁnalfollowup,therewere75(94.9%)patientswith
stable PSA levels: PSA  0.01, 40 cases; 0.02, 12; 0.03,
5; 0.04, 5; 0.1, 5; 1.0, 8. PSA failure developed in 4
(5.1%)ofthestudiedpatients.Clinicalstageswereasfollows:
T1b, 1 case; T1c, 2; T2, 1; pathological stages: pT2a, 1 case;
pT2b, 2; pT3, 1. In all cases studied, the actuarial biological
non-recurrence rate was 96.4% for the clinical stage T1b
and 95.7% for T1c at 58.9 months (Figure 1). PSA failure
developed in one of 4 patients with stage T2 cancer. The
actuarial biological non-recurrence rate was 98.2% for the
pathological stage pT2a at 88 months and 90.5% for pT2b
at 84 months (Figure 2). One of 2 patients with stage pT3
cancer developed PSA failure. Nonrecurrence rate of each
risk group according to The D’Amico classiﬁcation [17]i s
shown in Figure 3. PSA failure did not develop in the low-
risk group (stage T1c, T2a, and PSA level  10ng/mL and
Gleason score  6) of 32 patients. Biological non-recurrence
rate was 96.4% in the intermediate-risk group (stage T2b
or Gleason score of 7 or 10 < PSA level  20ng/mL) of
28 patients and 84.2% in the high-risk group (stage T2c or
PSA level > 20ng/mL or Gleason score  8) of 19 patients,
respectively.
To evaluate the distribution of prostate cancer near the
neurovascular bundle, we studied the result of pathological
examination of resected samples in 209 RTUR-PCa patients.
Cancer was detected at the 4 to 6 o’clock position in 44
patients (21%), at the 6 to 8 o’clock position in 38 patients
(18%), bilaterally (at the 4 to 8 o’clock position) in 74
patients (35%) and was not detected bilaterallyin 53 patients
(25%).
3.2. Result of FTUR-PCa. Concerning the 16 patients under-
went FTUR-PCa, the follow-up period ranged from 3 to 53
months (mean ± SD, 24.2 ± 15.4; median, 22.0), operation
time 80 to 120 minutes (mean ± SD, 92.5 ± 11.6; median,
90.0), and resected tissue weight 12 to 30 grams (mean ± SD,
21.0 ± 4.9; median, 20.0). Postoperative PSA was stabilized
between 0.07 and 0.406ng/mL (mean ± SD, 0.119 ± 0.111;
median, 0.090). The Gleason scores were as follows: 5, 1 case;
6,4;7,8;8,1;9,2.ClinicalstageswereT1cinallpatients,and
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pathological stages were as follows: pT2a, 10 cases and pT2b,
6. There were 11 cases underwent one lobe radical TUR and
5 cases underwent nerve sparing radical TUR. Eight (72.7%)
out of 11 patients underwent one lobe radical TUR had the
postoperative pathological stage of pT2a.
3.3. Operative Complications. TUR syndrome (systolic
hypotensionorelectrolyteabnormalitywhichneedsrepeated
correction to keep vital signs stable) and perioperative bleed-
ing (bleeding during the procedure or bladder tamponade
that requires blood transfusion) did not develope.
As for the postoperative complication of RTUR-PCa,
urinary incontinence was seen in about half of the patients
when a bag catheter was removed on the third postoperative
day. Incontinence soon improved until the third postoper-
ative week, and no patients complained of stress urinary
incontinence at all after the third postoperative month.
Bladder neck contracture developed in 28 patients (35.4%;
Grade IIIa by Clavien’s classiﬁcation) mostly three to four
months postoperatively. Other complications included one
pubic osteitis (1.3%; Grade II) and one acute epididymitis
(1.3%; Grade II). Erectile function was preserved after the
operation in 9 (50.0%) of the evaluated 18 sexually active
patients.
In FTUR-PCa, bladder neck contracture developed in
only 1 out of 16 patients. We experienced no stress urinary
incontinence, and erectile function was preserved in the all 5
patients underwent nerve-sparing TUR.
4. Discussion
4.1. Limitations of the Accuracy of Preoperative Staging. Out
of 79 patients with the clinical stage of T2a, 56 (70.9%)
patients were ﬁnally diagnosed to have the pathological stage
of pT2a disease with PSA non-recurrence rate of 98.2% at
a mean follow-up period of 58.9 months. These results may
supportthatFTUR-PCaisapromisingprocedure.Butitmay
be desirable to make the cancer distribution in the prostate
more accurate to select proper candidates of the procedure.
Only 27.3% to 35.1% of patients with unilateral cancer on
biopsy are reported to have cancer in one lobe on radical
prostatectomy samples [18, 19]. Crawford et al. report that
the concordant rate of laterality could be 76% on saturation
biopsy using a template [20] .A n da c c u r a c yo fb i o p s yi s
reported better in transperineal approach with a template
thantransrectalbiopsies[21].Fromtheresultofpathological
studies in our 209 RTUR-PCa, bilateral preservation of the
neurovascular bundle was thought to be possible in as many
as 25% of the patients and unilateral preservation in 39%.
Current biopsy procedures may be insuﬃcient to predict
cancer foci near the neurovascular bundle. Neurovascular
bundle reserving TUR, unilateral or bilateral, is worth trying
based on biopsy information, because TUR-PCa is possible
to repeat if postoperative PSA tends to rise gradually.
4.2. Comparison with Other Focal Therapies and Rationales
of FTUR-PCa. The number of patients with low-volume,
low-grade localized prostate cancer has increased after the
introduction of PSA into health check-up program [18, 22].
Ablation of only main cancer lesion (index cancer) in one
lobe by HIFU or cryotherapy is reported not to aﬀect the
prognosis as much [23, 24] because the second lesion, if it
exists, is usually as small as less than 0.5mL [25, 26]. But
these procedures have some serious drawbacks concerning
the selection of patients. Current methods of biopsy cannot
always predict another lesion to be treated, and followup
PSA criteria have not been established yet. Furthermore,
pathological samples cannot be obtained, resulting in the
inadequate ﬁnal pathological diagnosis. On the other hand,
FTUR-PCa is possible to search the second cancer focus after
the radical resection of main index cancer in one lobe and
advanced TUR in another lobe [27], resulting in the accurate
diagnosis of Gleason scores and the pathological stage. And
the second TUR may be possible, when necessary, using
PSA as an indicator of postoperative follow-up and cancer
recurrence. We therefore consider that FTUR-PCa could be
another possible procedure of focal therapy against prostate
cancer overcoming the drawbacks of HIFU and cryotherapy.
Our present result of FTUR-PCa seems satisfactory in cancer
control, urinary continence, and erectile function, though
thefollow-upperiodisasshortas24.2monthsinaverysmall
number of patients.
It is still controversial to support or not a mass screening
of prostate cancer because screening may lead to overdiagno-
sis and overtreatment. Active surveillance policy or watchful
waiting, which is an ultimate noninvasive procedure, is
then accepted to care for the patients with low-risk cancer
[28, 29]. But active surveillance seems still diﬃcult to select
a suitable patient, and the patient may feel anxiety about
cancer progression. Focal therapy is less invasive compared
to current standard treatment procedures such as radical
prostatectomy or irradiation therapy and may be a treatment
option with satisfactory cancer control and quality of life.
FTUR-PCa can expand the possibility of focal therapy, and
we think it is one of the feasible procedures to solve the
problems of overdiagnosis and overtreatment caused by PSA
screening of prostate cancer.
4.3. Possible Risk of FTUR-PCa and Some Other Considera-
tions. Dissemination of cancer cells may occur during TUR,
but the eﬀect on the clinical outcome is controversial [30–
32]. Our previous report could not ﬁnd any adverse eﬀects
on the prognosis of the studied patients [15, 16]. RTUR-PCa
can eradicate cancer cells like other current standard radical
therapy because repeated TUR is possible, and improvement
of the surgical results will be expected.
Extravasation of irrigation ﬂuid is sure to occur during
the operation, but there were no patients in whom water
intoxication developed with the lowest irrigation pressure,
and postoperative serum electrolytes were kept normal. At
present much safer operation is possible with the use of
a bipolar TUR system. The most frequent postoperative
complication was bladder neck contracture occurred in
35.4% of patients 3 to 4 months after surgery. This had been
anticipated because of aggressive bladder neck resection to
achieveradicality.ItwaseasilytreatedbyopticalurethrotomyAdvances in Urology 7
under caudal block on a day-surgery basis. In FTUR-PCa,
occurrence of bladder neck contracture is expected to be low
becauseitisaradicalprocedureinonlyoneaﬀectedlobewith
advanced TUR in the other lobe.
The eﬀect of chlormadinone acetate on postoperative
PSA must be considered in the present study. We could not
ﬁnd any reports that describe the duration of the suppressive
eﬀect of chlormadinone acetate in patients with prostate
cancer. But in patients with prostate hyperplasia 50mg/day
of chlormadinone acetate given for 16 weeks, PSA levels
are reported to return to the baseline levels 32 weeks after
discontinuation [33]. In the present study the eﬀect of
preoperative hormonal therapy on the most recent PSA
levels, therefore, can be minimal or negligible.
5. Conclusion
We could get a satisfactory cancer control with less invasive
procedure of RTUR-PCa and FTUR-PCa. Although the
results of long-term followup with more cases need to be
studied, the procedure we report here could be a potential
option of focal therapy against localized prostate cancer with
minimum adverse eﬀect on urinary continence and erectile
function.
References
[1] W. G. Reiner and P. C. Walsh, “An anatomical approach to the
surgical management of the dorsal vein and santorini’s plexus
duringradicalretropubicsurgery,”JournalofUrology,vol.121,
no. 2, pp. 198–200, 1979.
[2] B. Guillonneau, H. El-Fettouh, H. Baumert et al., “Laparo-
scopic radical prostatectomy: oncological evaluation after
1,000 cases at montsouris institute,” Journal of Urology, vol.
169, no. 4, pp. 1261–1266, 2003.
[3] J. Binder and W. Kramer, “Robotically-assisted laparoscopic
radicalprostatectomy,”BritishJournalofUrologyInternational,
vol. 87, no. 4, pp. 408–410, 2001.
[ 4 ]M .P o o n ,H .R u c k l e ,B .R .B a m s h a d ,C .T s a i ,R .W e b s t e r ,
and P. Liu, “Radical retropubic prostatectomy: bladder neck
preservation versus reconstruction,” Journal of Urology, vol.
163, no. 1, pp. 194–198, 2000.
[5] B. Rocco, A. Gregori, S. Stener et al., “Posterior recon-
struction of the rhabdosphincter allows a rapid recovery of
continence after transperitoneal videolaparoscopic radical
prostatectomy,”EuropeanUrology,vol.51,no.4,pp.996–1003,
2007.
[ 6 ]V .R .P a t e l ,R .F .C o e l h o ,K .J .P a l m e r ,a n dB .R o c c o ,
“Periurethral suspension stitch during robot-assisted laparo-
scopic radical prostatectomy: description of the technique and
continence outcomes,” European Urology,v o l .5 6 ,n o .3 ,p p .
472–478, 2009.
[7] Y. Kaiho, H. Nakagawa, Y. Ikeda et al., “Intraoperative
electrophysiological conﬁrmation of urinary continence after
radical prostatectomy,” Journal of Urology, vol. 173, no. 4, pp.
1139–1142, 2005.
[ 8 ]K .W a l l n e r ,G .M e r r i c k ,L .T r u e ,S .S u t l i e f ,W .C a v a n a g h ,
and W. Butler, “125Iv e r s u s103Pd for low-risk prostate cancer:
preliminary psa outcomes from a prospective randomized
multicenter trial,” International Journal of Radiation Oncology
Biology Physics, vol. 57, no. 5, pp. 1297–1303, 2003.
[9] A. J. Hayden, C. Catton, and T. Pickles, “Radiation therapy
in prostate cancer: a risk-adapted strategy,” Current Oncology,
vol. 17, no. 2, pp. 18–24, 2010.
[10] M. J. Zelefsky, Z. Fuks, M. Hunt et al., “High-dose intensity
modulated radiation therapy for prostate cancer: early toxicity
and biochemical outcome in 772 patients,” International
Journal of Radiation Oncology Biology Physics,v o l .5 3 ,n o .5 ,
pp. 1111–1116, 2002.
[11] G. M. Onik, J. K. Cohen, G. D. Reyes, B. Rubinsky, Z. Chang,
and J. Baust, “Transrectal ultrasound-guided percutaneous
radical cryosurgical ablation of the prostate,” Cancer, vol. 72,
no. 4, pp. 1291–1299, 1993.
[12] R. J. Babaian, B. Donnelly, D. Bahn et al., “Best practice
statement on cryosurgery for the treatment of localized
prostate cancer,” Journal of Urology, vol. 180, no. 5, pp. 1993–
2004, 2008.
[13] S. Madersbacher, M. Pedevilla, L. Vingers, M. Susani, and M.
Marberger, “Eﬀect of high-intensity focused ultrasound on
human prostate cancer in vivo,” Cancer Research, vol. 55, no.
15, pp. 3346–3351, 1995.
[14] L. Poissonnier, J. Y. Chapelon, O. Rouvi` ere et al., “Control of
prostate cancer by transrectal hifu in 227 patients,” European
Urology, vol. 51, no. 2, pp. 381–387, 2007.
[15] M. Morita and T. Matsuura, “Radical treatment of localized
prostate cancer by radical transurethral resection of the
prostate,” Current Urology, vol. 3, no. 2, pp. 87–93, 2009.
[16] M. Morita and T. Matsuura, “Radical transurethral resection
of the prostate: a possible radical procedure against localized
prostate cancer with almost no postoperative urinary incon-
tinence,” in Prostate Biopsy,N .K .B i s s a d a ,E d . ,p p .1 9 – 3 4 ,
InTech, Rijeka, Croatia, 1st edition, 2011.
[17] A. V. D’Amico, R. Whittington, S. B. Malkowicz et al.,
“Biochemical outcome after radical prostatectomy, external
beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer,” Journal of the American
Medical Association, vol. 280, no. 11, pp. 969–974, 1998.
[18] C. D. Scales, J. C. Presti, C. J. Kane et al., “Predicting unilateral
prostatecancerbasedonbiopsyfeatures:implicationsforfocal
ablative therapy-results from the search database,” Journal of
Urology, vol. 178, no. 4, pp. 1249–1252, 2007.
[19] B. Tareen, G. Godoy, A. Sankin, S. Temkin, H. Lepor, and
S. S. Taneja, “Can contemporary transrectal prostate biopsy
accurately select candidates for hemi-ablative focal therapy of
prostate cancer?” British Journal of Urology International, vol.
104, no. 2, pp. 195–199, 2009.
[20] E. D. Crawford, S. S. Wilson, K. C. Torkko et al., “Clinical
staging of prostate cancer: a computer-simulated study of
transperineal prostate biopsy,” British Journal of Urology
International, vol. 96, no. 7, pp. 999–1004, 2005.
[21] G. Onik and W. Barzell, “Transperineal 3D mapping biopsy
of the prostate: an essential tool in selecting patients for focal
prostate cancer therapy,” Urologic Oncology, vol. 26, no. 5, pp.
506–510, 2008.
[ 2 2 ]I .M e i e r s ,D .J .W a t e r s ,a n dD .G .B o s t w i c k ,“ P r e o p e r a t i v e
prediction of multifocal prostate cancer and application of
focaltherapy:review2007,”Urology,vol.70,no.6,supplement
1, pp. S3–S8, 2007.
[ 2 3 ]T .J .P o l a s c i k ,J .M .M a y e s ,L .S u n ,J .F .M a d d e n ,J .W .M o u l ,
and V. Mouraviev, “Pathologic stage T2a and T2b prostate
cancer in the recent prostate-speciﬁc antigen era: implications
for unilateral ablative therapy,” Prostate, vol. 68, no. 13, pp.
1380–1386, 2008.
[24] H. U. Ahmed, A. Freeman, A. Kirkham et al., “Focal therapy
for localized prostate cancer: a phase i/ii trial,” Journal of
Urology, vol. 185, no. 4, pp. 1246–1255, 2011.8 Advances in Urology
[25] M. Noguchi, T. A. Stamey, J. E. McNeal, and R. Nolley,
“Prognostic factors for multifocal prostate cancer in radical
prostatectomy specimens: lack of signiﬁcance of secondary
cancers,” Journal of Urology, vol. 170, no. 2 I, pp. 459–463,
2003.
[ 2 6 ]T .A .S t a m e y ,F .S .F r e i h a ,J .E .M c N e a l ,E .A .R e d w i n e ,
A. S. Whittemore, and H. P. Schmid, “Localized prostate
cancer: relationship of tumor volume to clinical signiﬁcance
for treatment of prostate cancer,” Cancer,v o l .7 1 ,n o .3 ,p p .
933–938, 1993.
[27] M. Morita and T. Matsuura, “An advanced buttraditional
technique of transurethral resection of the prostate not to
overlook stage T1 prostate cancer,” Current Urology, vol. 6, no.
1, pp. 21–26, 2012.
[28] A. Bill-Axelson, L. Holmberg, F. Fil´ en et al., “Radical prosta-
tectomy versus watchful waiting in localized prostate cancer:
the scandinavian prostate cancer group-4 randomized trial,”
Journal of the National Cancer Institute, vol. 100, no. 16, pp.
1144–1154, 2008.
[29] T. J. Wilt, M. K. Brawer, M. J. Barry et al., “The prostate cancer
intervention versus observation trial:va/nci/ahrq cooperative
studies program #407 (pivot): design and baseline results of a
randomized controlled trial comparing radical prostatectomy
to watchful waiting for men with clinically localized prostate
cancer,” Contemporary Clinical Trials, vol. 30, no. 1, pp. 81–87,
2009.
[30] E. S. Levine, V. J. Cisek, M. N. Mulvihill, and E. L. Cohen,
“Role of transurethral resection in dissemination of cancer of
prostate,” Urology, vol. 28, no. 3, pp. 179–183, 1986.
[31] M.J .Zelefsky ,W .F .W hitmoreJr .,S.A.Leibel,K.E.W allner ,Z.
Fuks,andC.B.Brendler,“Impactoftransurethralresectionon
the long-term outcome of patients with prostatic carcinoma,”
Journal of Urology, vol. 150, no. 6, pp. 1860–1865, 1993.
[32] V. Pansadoro, C. N. Sternberg, F. DePaula, A. Florio, D.
Giannarelli, and G. Arcangeli, “Transurethral resection of the
prostate and metastatic prostate cancer,” Cancer, vol. 68, no. 9,
pp. 1895–1898, 1991.
[33] K. Fujimoto, Y. Hirao, Y. Ohashi et al., “Changes in
serum prostate speciﬁc antigen and testosterone levels after
Chlormadinone acetate treatment in patients with benign
prostatichyperplasia:aprospectivemulticenterclinicalstudy,”
Acta Urologica Japonica, vol. 57, no. 4, pp. 177–183, 2011
(Japanese).